232 related articles for article (PubMed ID: 28178881)
1. Nanobiotech in big pharma: a business perspective.
Würmseher M; Firmin L
Nanomedicine (Lond); 2017 Mar; 12(5):535-543. PubMed ID: 28178881
[TBL] [Abstract][Full Text] [Related]
2. Overcoming the obstacles in the pharma/biotech industry: 2008 update.
Graul AI; Revel L; Rosa E; Cruces E
Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298
[TBL] [Abstract][Full Text] [Related]
3. Overcoming the challenges in the pharma/biotech industry.
Graul AI; Prous JR
Drug News Perspect; 2007; 20(1):57-68. PubMed ID: 17332900
[TBL] [Abstract][Full Text] [Related]
4. Overcoming further challenges in the pharma/biotech industry: 2007 update.
Graul AI; Cruces E; Revel L; Serradell N; Rosa E
Drug News Perspect; 2008; 21(1):44-58. PubMed ID: 18301809
[TBL] [Abstract][Full Text] [Related]
5. Financial Times Global Pharmaceutical & Biotechnology Conference 2009.
Scattereggia J
IDrugs; 2010 Jan; 13(1):26-9. PubMed ID: 20024844
[TBL] [Abstract][Full Text] [Related]
6. Biotech R&D still reeling.
Lawrence S
Nat Biotechnol; 2004 Sep; 22(9):1068. PubMed ID: 15340460
[No Abstract] [Full Text] [Related]
7. Commercialization of nanotechnology.
Hobson DW
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2009; 1(2):189-202. PubMed ID: 20049790
[TBL] [Abstract][Full Text] [Related]
8. The biotechnology innovation machine: a source of intelligent biopharmaceuticals for the pharma industry--mapping biotechnology's success.
Evens RP; Kaitin KI
Clin Pharmacol Ther; 2014 May; 95(5):528-32. PubMed ID: 24448474
[TBL] [Abstract][Full Text] [Related]
9. Issues and concerns in nanotech product development and its commercialization.
Kaur IP; Kakkar V; Deol PK; Yadav M; Singh M; Sharma I
J Control Release; 2014 Nov; 193():51-62. PubMed ID: 24933600
[TBL] [Abstract][Full Text] [Related]
10. Biotech business Down Under.
Beckley C
Nature; 2004 Jun; 429(6991 Suppl):5-9. PubMed ID: 15175704
[No Abstract] [Full Text] [Related]
11. Biotech acquisitions by big pharma: why and what is next.
Malik NN
Drug Discov Today; 2009 Sep; 14(17-18):818-21. PubMed ID: 19584004
[TBL] [Abstract][Full Text] [Related]
12. Biotech jostles with pharma for slice of HIV market.
Katsnelson A
Nat Biotechnol; 2006 Jan; 24(1):3-4. PubMed ID: 16404375
[No Abstract] [Full Text] [Related]
13. Patent threat in emerging economies shifts to biotech.
Jayaranam K
Nat Biotechnol; 2008 May; 26(5):481-3. PubMed ID: 18464760
[No Abstract] [Full Text] [Related]
14. Business: The billion-dollar biotech.
Dolgin E
Nature; 2015 Jun; 522(7554):26-8. PubMed ID: 26040878
[No Abstract] [Full Text] [Related]
15. New pharma-biotech company formation in India.
Saberwal G
Nat Biotechnol; 2006 May; 24(5):499-501. PubMed ID: 16680124
[No Abstract] [Full Text] [Related]
16. Prescription for an ailing pharmaceutical industry.
Demain AL
Nat Biotechnol; 2002 Apr; 20(4):331. PubMed ID: 11923826
[No Abstract] [Full Text] [Related]
17. Biotech companies adapt to big pharma mergers.
Niiler E
Nat Biotechnol; 2000 May; 18(5):487-8. PubMed ID: 10802607
[No Abstract] [Full Text] [Related]
18. Merck moves into biotech.
Kling J
Nat Biotechnol; 2006 Jul; 24(7):730. PubMed ID: 16841041
[No Abstract] [Full Text] [Related]
19. High Added Value - but Many Stumbling Blocks along the Way NTN Biotech Identifies where the Shoe Pinches.
Heinzelmann E
Chimia (Aarau); 2016; 70(1-2):118-20. PubMed ID: 26931230
[TBL] [Abstract][Full Text] [Related]
20. China spurs pharma innovation.
Hughes B
Nat Rev Drug Discov; 2010 Aug; 9(8):581-2. PubMed ID: 20671751
[No Abstract] [Full Text] [Related]
[Next] [New Search]
